Fate Therapeutics Financial Statements (FATE)
|
|
|
|
Report date
|
|
|
28.02.2022 |
28.02.2023 |
26.02.2024 |
05.03.2025 |
26.02.2026 |
|
13.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
55.8 |
96.3 |
63.5 |
13.6 |
6.65 |
|
6.32 |
|
Operating Income, bln rub |
|
|
-217.0 |
-308.4 |
-190.5 |
-210.3 |
-147.7 |
|
-139.4 |
|
EBITDA, bln rub |
? |
|
-211.1 |
-294.6 |
-172.2 |
-176.6 |
-127.0 |
|
-121.6 |
|
Net profit, bln rub |
? |
|
-212.2 |
-281.7 |
-160.9 |
-186.3 |
-136.3 |
|
-129.9 |
|
|
OCF, bln rub |
? |
|
-162.9 |
-248.2 |
-132.3 |
-122.9 |
-106.1 |
|
-103.1 |
|
CAPEX, bln rub |
? |
|
50.7 |
35.6 |
6.15 |
0.730 |
5.95 |
|
5.00 |
|
FCF, bln rub |
? |
|
-213.6 |
-283.8 |
-138.4 |
-123.6 |
-112.0 |
|
-108.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
267.0 |
390.9 |
96.9 |
223.9 |
141.4 |
|
142.8 |
|
Cost of production, bln rub |
|
|
5.85 |
13.8 |
157.2 |
0.000 |
12.9 |
|
2.92 |
|
R&D, bln rub |
|
|
215.5 |
320.5 |
172.6 |
135.0 |
107.8 |
|
100.5 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
921.5 |
705.6 |
506.2 |
440.7 |
318.9 |
|
284.9 |
|
Net Assets, bln rub |
? |
|
678.8 |
483.9 |
368.4 |
318.7 |
207.2 |
|
179.7 |
|
Debt, bln rub |
|
|
114.8 |
109.3 |
103.5 |
85.3 |
77.8 |
|
76.8 |
|
Cash, bln rub |
|
|
615.9 |
436.2 |
315.2 |
279.1 |
203.7 |
|
174.8 |
|
Net debt, bln rub |
|
|
-501.1 |
-326.9 |
-211.6 |
-193.8 |
-125.8 |
|
-98.0 |
|
|
Ordinary share price, rub |
|
|
58.5 |
|
|
1.65 |
0.983 |
|
1.96 |
|
Number of ordinary shares, mln |
|
|
94.7 |
96.8 |
98.4 |
113.7 |
118.8 |
|
120.0 |
|
|
Market cap, bln rub |
|
|
5 544 |
0 |
0 |
188 |
117 |
|
235 |
|
EV, bln rub |
? |
|
5 043 |
-327 |
-212 |
-6 |
-9 |
|
137 |
|
Book value, bln rub |
|
|
679 |
484 |
368 |
319 |
207 |
|
180 |
|
|
EPS, rub |
? |
|
-2.24 |
-2.91 |
-1.64 |
-1.64 |
-1.15 |
|
-1.08 |
|
FCF/share, rub |
|
|
-2.25 |
-2.93 |
-1.41 |
-1.09 |
-0.94 |
|
-0.90 |
|
BV/share, rub |
|
|
7.16 |
5.00 |
3.74 |
2.80 |
1.74 |
|
1.50 |
|
|
EBITDA margin, % |
? |
|
-378.1% |
-305.9% |
-271.1% |
-1 295% |
-1 911% |
|
-1 925% |
|
Net margin, % |
? |
|
-379.9% |
-292.5% |
-253.3% |
-1 366% |
-2 051% |
|
-2 057% |
|
FCF yield, % |
? |
|
-3.85% |
|
|
-65.9% |
-96.0% |
|
-46.1% |
|
ROE, % |
? |
|
-31.3% |
-58.2% |
-43.7% |
-58.4% |
-65.8% |
|
-72.3% |
|
ROA, % |
? |
|
-23.0% |
-39.9% |
-31.8% |
-42.3% |
-42.7% |
|
-45.6% |
|
|
P/E |
? |
|
-26.1 |
0.00 |
0.00 |
-1.01 |
-0.86 |
|
-1.81 |
|
P/FCF |
|
|
-26.0 |
0.00 |
0.00 |
-1.52 |
-1.04 |
|
-2.17 |
|
P/S |
? |
|
99.3 |
0.00 |
0.00 |
13.8 |
17.6 |
|
37.2 |
|
P/BV |
? |
|
8.17 |
0.00 |
0.00 |
0.59 |
0.56 |
|
1.31 |
|
EV/EBITDA |
? |
|
-23.9 |
1.11 |
1.23 |
0.04 |
0.07 |
|
-1.12 |
|
Debt/EBITDA |
|
|
2.37 |
1.11 |
1.23 |
1.10 |
0.99 |
|
0.81 |
|
|
R&D/CAPEX, % |
|
|
425.1% |
901.0% |
2 805% |
18 493% |
1 811% |
|
2 011% |
|
|
CAPEX/Revenue, % |
|
|
90.8% |
36.9% |
9.68% |
5.36% |
89.6% |
|
79.1% |
|
| Fate Therapeutics shareholders |
